STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] Cresco Labs Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of November, 2025
000-56241
(Commission File Number)
Cresco Labs Inc.
(Exact name of Registrant as specified in its charter)
600 W. Fulton Street, Suite 800
Chicago, IL 60661

(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☐    Form 40-F ☒



Exhibit Index
Exhibit No.Description
99.1
Unaudited Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2025 and 2024
99.2
Management Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2025 and 2024
99.3
News Release dated November 5, 2025




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CRESCO LABS INC.
Date: November 7, 2025
By:/s/ Charles Bachtell
Charles Bachtell
Chief Executive Officer


Cresco Labs

OTC:CRLBF

CRLBF Rankings

CRLBF Latest News

CRLBF Latest SEC Filings

CRLBF Stock Data

369.38M
332.59M
1.72%
7.71%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Chicago